Cell Free DNA for the Diagnosis and Treatment in Early NSCLC

NCT03791034 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2021-05-11

No results posted yet for this study

Summary

The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.

Conditions

Sponsors & Collaborators

  • Guardant Health, Inc.

    collaborator INDUSTRY
  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Jhingook Kim, MD · Samsung Medical Center

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-28
Primary Completion
2021-12-31
Completion
2026-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03791034 on ClinicalTrials.gov